Clinical Trials Browser

Phase 2 × Breast Neoplasms × cc-486 × Clear all

NCT02374099 2018-12-14

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Phase 2 Terminated

97 enrolled 18 charts

Breast Neoplasms